First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan
Trial Details
- NCT ID
- NCT06667167
- Phase
- PHASE2
- Sponsor
- Nir Peled
- Status
- RECRUITING
- Cancer Type
- Lung Cancer
- Interventions
- Locations (sample)
- Jerusalem, Israel, Israel|31.76904,35.21633
Key Eligibility Criteria
- Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically or cytologically confirmed dia…
- The participant has not been previously treated with systemic therapy for ES SCLC (i.e., the disease is treatment naïve).
- Note: Participants previously treated for limited SCLC will be allowed with disease-free survival (DFS) of 6 months after completion of all treatment.
- Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →